Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence
Kottke, Tim, Evgin, Laura, Shim, Kevin G., Rommelfanger, Diana, Boisgerault, Nicolas, Zaidi, Shane, Diaz, Rosa Maria, Thompson, Jill, Ilett, Elizabeth, Coffey, Matt , Selby, Peter, Pandha, Hardev, Harrington, Kevin, Melcher, Alan and Vile, Richard (2017) Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence Cancer Immunology Research, 5 (11). pp. 1029-1045.
![]() |
Text
Subversion of NK-cell.docx - Accepted version Manuscript Download (149kB) |
|
![]() |
Slideshow
Subversion of NK-cell - supplementary materials - New Table 1.pptx - Supplemental Material Download (51kB) |
|
![]() |
Slideshow
Subversion of NK-cell - supplementary materials - New Table 2.pptx - Supplemental Material Download (95kB) |
|
|
Other (Illustrations + tables)
Subversion of NK-cell - supplementary materials - illustrations + tables.pdf - Supplemental Material Download (1MB) | Preview |
Abstract
Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the subversion of two key elements of innate immune surveillance. In the first, the role of TNFalpha changes from an antitumor effector against primary tumors into a growth promoter for MRD. Second, whereas primary tumors induced a natural killer (NK)-mediated cytokine response characterized by low IL6 and elevated IFNgamma, PD-L1hi MRD cells promoted the secretion of IL6 but minimal IFNgamma, inhibiting both NK cell and T-cell surveillance. Tumor recurrence was promoted by trauma- or infection-like stimuli inducing VEGF and TNFalpha which stimulated the growth of MRD tumors. Finally, therapies which blocked PD1, TNFalpha or NK cells delayed or prevented recurrence. These data show how innate immune surveillance mechanisms, which control infection and growth of primary tumors, are exploited by recurrent, competent tumors and identifies therapeutic targets in patients with MRD known to be at high risk of relapse.
Item Type: | Article | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Divisions : | Faculty of Health and Medical Sciences > School of Biosciences and Medicine | ||||||||||||||||||||||||||||||||||||||||||||||||
Authors : |
|
||||||||||||||||||||||||||||||||||||||||||||||||
Date : | 15 October 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||
DOI : | 10.1158/2326-6066.CIR-17-0175 | ||||||||||||||||||||||||||||||||||||||||||||||||
Copyright Disclaimer : | Copyright ©2017, American Association for Cancer Research. | ||||||||||||||||||||||||||||||||||||||||||||||||
Uncontrolled Keywords : | Immune responses to cancer; Immunomodulation; Tumor resistance to immune response | ||||||||||||||||||||||||||||||||||||||||||||||||
Depositing User : | Clive Harris | ||||||||||||||||||||||||||||||||||||||||||||||||
Date Deposited : | 02 Nov 2017 10:57 | ||||||||||||||||||||||||||||||||||||||||||||||||
Last Modified : | 16 Oct 2018 02:08 | ||||||||||||||||||||||||||||||||||||||||||||||||
URI: | http://epubs.surrey.ac.uk/id/eprint/844801 |
Actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year